Opko Health Inc. (NYSE:OPK) announced the appointment of Dr. Ronald Trust as Vice President of Regulatory Affairs of OPKO Pharmaceuticals.
Prior to joining OPKO, Ron held senior regulatory positions at Allergan (through its acquisition of Durata Therapeutics), spent over 16 years at Pfizer in various regulatory affairs positions, and most recently worked as an independent consultant providing strategic regulatory consulting services to the pharmaceutical industry. Ron received his PhD in organic chemistry from the California Institute of Technology and he also holds a Masters in Business Administration from Fairleigh Dickinson University.
“Ron has over 40 years of pharmaceutical industry development experience, including over 30 years in regulatory affairs, safety/risk management and quality assurance, which will be of tremendous value as we continue to bring our product candidates to market,” said Phillip Frost, M.D., Chairman and Chief Executive Officer of OPKO. (Original Source)
Shares of Opko Health closed last Thursday at $11.28, down $0.05 or -0.44%. OPK has a 1-year high of $19.20 and a 1-year low of $7.12. The stock’s 50-day moving average is $9.54 and its 200-day moving average is $9.57.
On the ratings front, Opko Health has been the subject of a number of recent research reports. In a report issued on March 15, Jefferies Co. analyst Brandon Couillard reiterated a Hold rating on OPK. Separately, on March 1, Oppenheimer’s Rohit Vanjani maintained a Hold rating on the stock .
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Brandon Couillard and Rohit Vanjani have a total average return of 9.4% and 10.9% respectively. Couillard has a success rate of 71.3% and is ranked #252 out of 3742 analysts, while Vanjani has a success rate of 50.8% and is ranked #216.
Opko Health Inc is a biopharmaceutical and diagnostics company. The Company is engaged in the research and development of pharmaceutical products and vaccines.